Osimertinib, a third‐generation tyrosine kinase inhibitor, is widely used as a first‐line treatment for patients with epidermal growth factor receptor (EGFR) mutated non‐small cell lung cancer (NSCLC).1, 2. Here, EGFR is linked to lung cancer.